Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.

Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about SURMOUNT-ADOLESCENTS- 2

Principal Investigator

Gnanagurudasan Prakasam, M.D.

Co-Investigator(s)

Ulhas Nadgir, MD, Meredith Brady, N.P., Niyati Skaria, MD